A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Key facts
- Where
- Albany, Beverly Hills, Boca Raton, Boston, Bradenton, Cincinnati, Columbus, Covina, Detroit, Falls Church, Flint, Houston, Huntsville, Manassas, Miami, Miami Lakes, Minneapolis, Naples, New York, Northridge, Overland Park, Palo Alto, Philadelphia, Rochester, Royal Oak, San Diego, San Francisco, Summit, and Winston-Salem, United StatesSee the 35 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT05646381, who can take part
Where in United States
- Capital Cardiology AssociatesAlbany, United StatesContact: Shreya ShahTaking people
- Cardiovascular Res FoundBeverly Hills, United StatesContact: Juan RamosTaking people
- National Heart InstituteBeverly Hills, United StatesContact: Maria FloresTaking people
- Excel Medical Clinical Trials, LLCBoca Raton, United StatesContact: Novartis PharmaceuticalsNo longer taking part
- Brigham and Womens Hosp Harvard Med SchoolBoston, United StatesContact: Sam WongTaking people
- Massachusetts General HospitalBoston, United StatesContact: Victoria ViscosiTaking people
- Tufts Medical CenterBoston, United StatesContact: Veronique RecileTaking people
- Nova Clinical Research, LLCBradenton, United StatesContact: Sade AndrewsTaking people
- Lindner Ctr At The Christ HospCincinnati, United StatesContact: Meghan GroneTaking people
- Ohio State UniversityColumbus, United StatesContact: Novartis PharmaceuticalsNo longer taking part
- Flourish Clinical Resrch CovinCovina, United StatesContact: Sarita GarciaTaking people
- Henry Ford HospitalDetroit, United StatesContact: Jodi Carter, BS, CCRPTaking people
- Virginia HeartFalls Church, United StatesContact: Oyinda AgbaleTaking people
- AA Medical Research CenterFlint, United StatesContact: Fayyaz ShahTaking people
- Orion MedicalHouston, United StatesContact: Lena Olivera PerezTaking people
- Texas Heart InstituteHouston, United StatesContact: Dominique RobertsonTaking people
- Heart Center Research, LLCHuntsville, United StatesContact: Amy WilliamsTaking people
- Carient Heart and VascularManassas, United StatesContact: Hameeda TasneemTaking people
- Flourish Res Acq LLC North MiamiMiami, United StatesContact: Ashlee SealyTaking people
- Inpatient Research Clinical LLCMiami Lakes, United StatesContact: Dora GutierrezTaking people
- University of MinnesotaMinneapolis, United StatesContact: Michelle PittTaking people
- Minneapolis Heart InstituteMinneapolis, United StatesContact: Novartis PharmaceuticalsNo longer taking part
- Advanced Research for Health Improvement LLCNaples, United StatesContact: Novartis PharmaceuticalsNo longer taking part
- Icahn School of Med at Mt SinaiNew York, United StatesContact: Jay Krishna KatragaddaTaking people
- New York - Presbyterian HospitalNew York, United StatesContact: Novartis PharmaceuticalsNo longer taking part
- Valley Clinical TrialsNorthridge, United StatesContact: Haydee GutierrezTaking people
- Midwest Heart and Vascular SpecOverland Park, United StatesContact: Elizabeth FulksTaking people
- Stanford University Medical CenterPalo Alto, United StatesContact: Tamara BazouziTaking people
- Perelman School of MedicinePhiladelphia, United StatesContact: Manali ShahTaking people
- Strong Memorial HospitalRochester, United StatesContact: Ferogh ShakouriTaking people
- William Beaumont HospitalRoyal Oak, United StatesContact: Rachel WylieTaking people
- University of California San DiegoSan Diego, United StatesContact: Ruby SwaimTaking people
- UC San Francisco Medical CenterSan Francisco, United StatesContact: Liliann ZouTaking people
- Overlook Medical CenterSummit, United StatesContact: Rosmery MontesinoTaking people
- Wake Forest University Baptist Medical CenterWinston-Salem, United StatesContact: Donna DavisTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT05646381EU 2022-502135-19-00
- Record updated
- 23 June 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.Read full original descriptionShow less
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Inclusion: Male and female ≥50 to <80 years of age at Screening Part II; Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory; Mild or moderate calcific aortic valve stenosis; At the randomization visit, participant must be optimally treated for existing CV risk factors.
Exclusion: Uncontrolled hypertension; History of malignancy of any organ system; History of hemorrhagic stroke or other major bleeding; Active liver disease or hepatic dysfunction; Significant kidney disease; Platelet count ≤ LLN; Severe calcific aortic valve stenosis; Pregnant or nursing women; Other protocol-defined inclusion/exclusion criteria may apply.